Of the 100 breast cancer subjects, 17% of the breast cancer subjects were ER-positive, 18% of the breast cancer subjects were HER2-positive, 16% of the breast cancer subjects were ER/PR-positive, 18% of the breast cancer subjects were ER/HER2-positive, 15% of the breast cancer subjects were ER/PR/HER2-positive, and 16% of the breast cancer subjects had TNBC. This evidence concerns the gene ERBB2 and breast carcinoma.